Cognitive, emotional, and behavioral disorders in hypertensive patients
https://doi.org/10.14412/2074-2711-2018-4-116-122
Abstract
The brain is a natural target organ in hypertension and, as shown by some clinical observations, it is affected earlier than other organs and systems. Due to the specific features of the anatomy of cerebral circulation, hypertensive microangiopathy leads primarily to damage to the subcortical basal ganglia and deep white matter. Clinically, this is manifested by a concurrence of predominantly subcortical cognitive impairment and emotional and behavioral disorders as depression, emotional lability, and apathy. Some features of depression, such as the prevalence of anhedonia and fatigue and the significant severity of cognitive and somatic symptoms in an elderly person with vascular disease, suggest its organic nature (vascular depression).
About the Authors
S. K. Abduraimova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021
V. V. Zakharov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Vladimir Vladimirovich Zakharov - Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine
11, Rossolimo St., Build. 1, Moscow 119021
A. R. Kabaeva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021
References
1. Chirin AS. Arterial hypertension as a socially significant problem of modern Russia. 2016. http://medconfer.com/node/5903
2. Eremina OV. Kognitivnye narusheniya u bol'nykh arterial'noigipertoniei (chastota, diagnostika, lechenie). Dis. cand. med. sci. 2007. 150 p.
3. Hering D, Narkiewicz K. Sympathetic nervous system and arterial hypertension: new perspectives, new data. Kardiol Pol. 2013;71(5):441-6. doi: 10.5603/KP.2013.0089.
4. Lavrova DI. Hypertension as a cause of disability of the population in Russia. Medicus. 2015;5(5). (In Russ.).
5. Zakharov VV, Vakhnina NV, Parfenov VA. Cognitive impairment and their treatment in hypertension. Meditsinskii sovet. Nevrologiya. 2017;(1S):6-12. (In Russ.).
6. Vakhnina NV. Cognitive impairment in hypertension. Meditsinskii sovet. Nevrologiya. 2015;(5):34-9. (In Russ.).
7. Parfenov VA, Starchina YuA. Cognitive disorders in patients with hypertension and their treatment. Nevrologiya, neirop-sikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(1): 27-33. (In Russ.). doi: 10.14412/2074-2711-2011-130
8. Parfenov VA, Starchina YuA. Cognitive disorders and their treatment in arterial hypertension. Nervnye bolezni. 2015;(1):16-22. (In Russ.).
9. Treshchinskaya MA. Arterial hypertension and cerebrovascular pathology. Novini meditsini ta farmatsii. Nevrologiya. 2009;(299). (In Russ.).
10. Laurent S, Boutouyrie P. The structural factor of hypertension. Large and small artery alterations. Circ Res. 2015 Mar 13;116(6):1007-21. doi: 10.1161/CIRCRESAHA.116.303596.
11. Rizzoni D, Porteri E, Boari GE, et al. Prognostic significance of smallartery structure in hypertension. Circulation. 2003 Nov 4;108(18):2230-5. Epub 2003 Oct 13.
12. Levin OS, Damulin IV. Diffuse changes of the white matter (leykoareosis) and the problem of vascular dementia. In: Yakhno NN, Damulin IV, editors. Dostizheniya v neirogeriatrii [Advances in neurogeriatric]. Moscow: MMA; 1995. P. 189-228.
13. Levin OS. Encephalopathy: from the pathogenesis to treatment. Trudnyipatsient. 2010;(4):8-15. (In Russ.).
14. Damulin IV, Ekusheva EV. Dementia due to cerebral small vessel damage: Current ideas on its pathogenesis and therapy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(4):94-100. (In Russ.). doi: 10.14412/2074-2711-2014-4-94-100
15. Abramenko YuV, Yakovlev NA. Cognitive and emotional disorders in men and women with dyscirculato-ry encephalopathy. Saratovskii nauchno-med-itsinskiizhurnal. 2012;8(2):70-4. (In Russ.).
16. Shmidt EV, Lunev DK, Vereshchagin NV. Sosudistye zabolevaniya golovnogo i spinnogo mozga [Vascular diseases of the brain and spinal cord]. Moscow: Meditsina; 1976. 284 p.
17. Zakharov VV, Vakhnina NV. Cognitive and emotional-behavioral disorders in patients with dyscirculatory encephalopathy. Consilium medicum. 2013;15(2):10-5. (In Russ.).
18. Zakharov VV, Vakhnina NV. Cognitive impairment in hypertension. Nervnye bolezni. 2013;(3):16-21. (In Russ.).
19. Emelin AYu. Cognitive impairments in cerebrovascular disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(4):11-8. (In Russ.). Doi: 10.14412/2074-2711-2014-4-11-18
20. Zakharov VV, Vakhnina NV. Stroke and cognitive disorders. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(2):8-16. (In Russ.). Doi: 10.14412/2074-2711-2011-141
21. Starchina YuA, Parfenov VA, Chazova IE, et al. Cognitive disorders in patients with hypertension. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;(4):39-43. (In Russ.)
22. Elias MF, Goodell AL, Dore GA. Hypertension and cognitive functioning. A perspective in Historical Context. Hypertension. 2012 Aug;60(2):260-8. doi: 10.1161/HYPER-TENSIONAHA.111.186429. Epub 2012 Jul 2.
23. Morozova OG, Yaroshevskii AA, Lipinskaya YaV. Ways to optimize the treatment of cognitive impairment in patients with hypertension. Novini meditsini ta farmatsii. 2016;(3):8-10. (In Russ.)
24. Iadecola C. Hypertension and dementia. Hypertension. 2014 Jul;64(1):3-5. doi: 10.1161/HYPERTENSIONAHA.114.03040. Epub 2014 Apr 28.
25. Elkins JS, Yaffe K, Cauley JA, et al. Preexisting hypertension and the impact of stroke on cognitive function. Ann Neurol. 2005 Jul;58(1):68-74.
26. Starr JM, Whalley LJ, Inch S, Shering PA. Blood pressure and cognitive functions in healthy old people. JAm Geriatr Soc. 1993 Jul;41(7):753-6.
27. Vakhnina NV, Milovanova OV, Grinyuk VV. Neurological disorders in hypertensive patients. Nevrologiya, neiropsikhia-triya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015;7(4):57-64. (In Russ.). doi: 10.14412/2074-2711-2015-4-57-64
28. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996 Apr 27;347(9009):1141-5.
29. Qiao J, Lu WH, Wang J, et al. Vascular risk factors aggravate the progression of Alzheimer's disease: a 3-year follow-up study of Chinese population. Am J Alzheimers Dis Other Demen. 2014 Sep;29(6):521-5. doi: 10.1177/1533317514522853. Epub 2014 Feb 21.
30. Kivipelto M, Helkala EL, HRnninen T, et al. A Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 2001 Jun 26;56(12):1683-9.
31. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study. JAMA. 1997 Mar 12;277(10):813-7.
32. Li JQ, Tan L, Wang HF, et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry. 2016 May;87(5):476-84. doi: 10.1136/jnnp-2014-310095. Epub 2015 May 22.
33. Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1299-306. doi: 10.1136/jnnp-2015-310548. Epub 2015 Aug 20.
34. Power MC, Weuve J, Gagne JJ, et al. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology. 2011 Sep;22(5):646-59. doi: 10.1097/EDE.0b013e31822708b5.
35. 0stergaard SD, Mukherjee S, Sharp SJ, et al. Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. PLoS Med. 2015 Jun 16;12(6):e1001841; discussion e1001841. doi: 10.1371/journal.pmed.1001841.eCollection 2015 Jun.
36. Zakharov VV, Voznesenskaya TG. Nervno-psikhicheskie narusheniya: diagnostich-eskie testy [Neuropsychiatric disorders: diagnostic tests]. Moscow: MEDpress-inform; 2016. 320 p.
37. Morris R, Becker J. Cognitive neuropsychology of Alzheimer's disease. Oxford: Oxford University press; 1996. 421 p.
38. Vein AM, Voznesenskaya TG, Golubev VL, Dyukova GM. Depressiya v nevrologicheskoipraktike [Depression in neurological practice]. Moscow: MIA; 2007. 197 p.
39. Voznesenskaya TG. Depression in cerebrovascular diseases. Nevrologiya, neirop-sikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2009;1(2):9-12. (In Russ.)]. Doi: 10.14412/2074-2711-2009-31
40. So nmez YE, Erden Aki SO. Vascular Depression. Archives of Neuropsychiatry. 2013;50:1-8.
41. Alexopoulos GS, Bruse ML, Silbersweing D, et al. Vascular depression: a new view of late-onset depression. Dialogues Clin Neurosci. 1999 Sep;1(2):68-80.
42. Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. MolPsychiatry. 2013 Sep;18(9):963-74. doi: 10.1038/mp.2013.20. Epub 2013 Feb 26.
43. Alexopoulos GS, Meyers BS, Young RC, et al. Vascular depression hypothesis. Arch Gen Psychiatry. 1997 Oct;54(10):915-22.
44. Alexopoulos GS, Kiosses DN, Klimstra S, et al. Clinical presentation of the 'depression-executive dysfunction syndrome' of late life. Am JGeriatrPsychiatry. 2002 Jan-Feb;10(1):98-106.
45. Alexopolos G. The depression - executive dysfunction syndrome of late life. Am J Geriatr Psychiatry. 2001 Winter;9(1):22-9.
46. Yanakaeva T.A. Depressive disorders in vascular diseases of the brain. Russian Medical Journal. 1998;(6):57-60. (In Russ.).
47. Zakharov VV. Moderate cognitive disorders as a multidisciplinary problem. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2010;2(2):5-10. (In Russ.). Doi: 10.14412/2074-2711-2010-77
48. Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции. Москва: МЕДпресс-информ; 2010. 272 с. [Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii [Dementias]. Moscow: MEDpress-inform; 2010. 272 p.]
49. Kanner AM. Depression in neurological disorders. Lundbec Inst; 2005. 161 p.
50. Drevets WC. Neuroplasticity in mood disorders. In: Dialogues in clinical neuroscience. Dialogues Clin Neurosci. 2004 Jun;6(2):199-216.
51. Chow SM, Hamagami F, Nesselroade JR. Age differences in dynamical emotion-cognition linkages. Psychol Aging. 2007 Dec;22(4):765-80. doi: 10.1037/0882-7974.22.4.765.
52. Shear K, Frank E, Houck PR, Reynolds CF. 3rd. Treatment of complicated grief: a randomized controlled trial. JAMA. 2005; 293(21):2601-8.
53. Newson RS, Boelen PA, Hek K, et al. The prevalence and characteristics of complicated grief in older adults. J Affect Disord. 2011 Jul;132(1-2):231-8. doi: 10.1016/j.jad.2011.02.021. Epub 2011 Mar 12.
54. Bryant RA. Grief as a psychiatric disorder. Br J Psychiatry. 2012 Jul;201(1):9-10. doi: 10.1192/bjp.bp.111.102889.
55. Haag MD, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology. 2009 May 19;72(20):1727-34. doi: 10.1212/01.wnl.0000345062.86148.3f. Epub 2009 Feb 18.
56. Perila R, White LR, Masaki K, et al. Reducing the risk of dementia: efficacy of long term treatment of hypertension. Stroke. 2006 May;37(5):1165-70. Epub 2006 Apr 6.
57. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised doubleblind placebo controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 Oct 24;352(9137):1347-51.
58. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindo-pril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003 May 12;163(9):1069-75.
59. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005 Jun;36(6):1218-26. Epub 2005 May 5.
60. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013 Jun;31(6):1073-82. doi: 10.1097/HJH.0b013e3283603f53.
61. Mishchenko T, Shestopalova L, Kozhevnikova V i dr. Hypertensive discircu-latory encephalopathy and vascular dementia. Experience of using Fasam. Liki Ukraini. 2005;(9):57-60. (In Ukr.).
62. Trompet S, Van Vliet P, De Craen AJ, et al. Pravastatin and cognitive function in the elderly: results of the PROSPER study. J Neurol. 2010 Jan;257(1):85-90. doi: 10.1007/s00415-009-5271-7. Epub 2009 Aug 4.
63. Diener HC, Sacco RL, Yusuf S, et al. Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study Group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a doubleblind, active and placebo controlled study. Lancet Neurol. 2008 Oct;7(10):875-84. doi: 10.1016/S1474-4422(08)70198-4. Epub 2008 Aug 29.
64. Price JF, Stewart MC, Deary IJ, et al. Low dose aspirin and cognitive function in middle aged to elderly adults: randomized controlled trial. BMJ. 2008 Sep 1;337:a1198. doi: 10.1136/bmj.a1198.
Review
For citations:
Abduraimova S.K., Zakharov V.V., Kabaeva A.R. Cognitive, emotional, and behavioral disorders in hypertensive patients. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):116-122. (In Russ.) https://doi.org/10.14412/2074-2711-2018-4-116-122
Views: 910
Email this article 